PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024
Conference Call and Webcast at 8:30 AM Eastern Time
美東時間上午8:30召開電話會議和網絡會議
NEW YORK, July 30, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, August 13, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's second quarter 2024 financial results.
美國紐約，2024年7月30日 /美通社/ -- PAVmed Inc.(納斯達克: PAVm, PAVMZ)(“PAVmed”或“公司”), 是一家進入商業化階段的多元化醫療技術公司，致力於醫療器械、診斷和互聯網醫療等領域，今天宣佈將於2024年8月13日星期二美東時間上午8:30舉行業務更新電話會議和網絡會議。在該通電話中, PAVmed的董事長兼首席執行官Lishan Aklog將提供業務更新，包括公司運營和增長策略的概述。此外，PAVmed的總裁兼首席財務官Dennis McGrath還將討論公司2024年第二季度的財務業績。
The webcast will be available at the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join.
網絡會議可在公司網站pavmed.com的股東關係部分上觀看。手機用戶可撥打 1-800-836-8184，國際用戶可撥打 1-646-357-8785，參加會議請點擊操作員，並輸入會議名稱“PAVmed業務更新”。
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.
電話會議結束後，30天內可在公司pavmed.com的投資者關係部分查看重播。
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other main subsidiary, Veris Health, is focused on commercialization of its digital cancer care platform with physiologic data collection, symptom reporting and telehealth functions, designed to improve personalized cancer care through remote patient monitoring. Veris has also been developing an implantable physiologic monitor containing biologic sensors capable of generating continuous data on key physiologic parameters known to predict adverse outcomes in cancer patients undergoing treatment.
關於PAVmed
PAVmed Inc.是一家進入商業化階段的醫療技術公司，致力於醫療器械、診斷和互聯網醫療等領域。其子公司Lucid Diagnostics (Nasdaq:LUCD)是一家商業化階段乳腺癌預防醫學診斷公司，推廣用於早期檢測食管癌前病變的EsoGuard食管DNA測試和EsoCheck食管細胞採集器，這是首個也是唯一的廣泛應用於食管癌前病變早期檢測的商業化工具，以減輕食管癌的死亡風險。其另一主要子公司Veris Health專注於具有生理數據收集、症狀報告和遠程醫療功能的數字癌症護理平台的商品化，旨在通過遠程病人監測，提高個性化癌症護理水平。Veris還在開發一款植入式生理監測器，包含具有連續性生物傳感器的重要生理參數，能夠預測癌症患者在治療中發生的不良結果。
For more and for more information about PAVmed, please visit pavmed.com.
更多有關PAVmed的信息，請訪問pavmed.com。
For more information about Lucid Diagnostics, please visit luciddx.com.
有關Lucid Diagnostics的更多信息，請訪問luciddx.com。
For more information about Veris Health, please visit verishealth.com.
有關Veris Health的更多信息，請訪問verishealth.com。
SOURCE PAVmed Inc.
PAVmed Inc. 來源。